pdf   xlsx method abbreviations

Extensive stage SCLC (Es-SCLC) - maintenance (M), Immune checkpoint association , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.92 [0.75, 1.12]< 10%1 study (1/-)79.2 %NAnot evaluable crucial-
progression or deaths (PFS) 0.72 [0.60, 0.87]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 2.33 [1.11, 4.90]> 10%1 study (1/-)98.7 %NAnot evaluable non important-

safety endpoints 00

TRAE (any grade) 4.23 [2.89, 6.20]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE (grade 3-4) 12.44 [7.59, 20.41]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 7.05 [0.86, 57.70]< 10%1 study (1/-)3.5 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 60.82 [14.79, 250.13]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons